Login to Your Account

Financings Roundup

PTC Gets $50M to Launch Ataluren, Further Studies

By Catherine Hollingsworth

Wednesday, December 23, 2009
PTC Therapeutics Inc. has completed a $50 million financing, the proceeds for which will be used to prepare for the anticipated launch of the drug in Duchenne's muscular dystrophy in the first half of 2011. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription